Introduction
Primary myelofibrosis (PMF) as well as MF that develops during the course of essential thrombocythemia (ET) or polycythemia vera (PV; post-ET or PV MF) are characterized by the constitutive mobilization of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs) and the establishment of extramedullary hematopoiesis. [1] [2] [3] [4] [5] MF originates at the level of the HSC 6 and is associated with a number of acquired mutations that activate Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Several JAK1/2 inhibitors including ruxolitinib have been shown to reduce spleen sizes in MF patients independent of their JAK2 mutational status. [23] [24] [25] [26] To date, the mechanism underlying the reduction of splenomegaly observed with JAK2 inhibitor therapy remains the subject of speculation. Recently, we documented that splenic (SP) MF-stem cells (MF-SCs) and those in the peripheral blood (PB) have distinct properties, 27 suggesting that their responses to JAK2 inhibitors might differ. We, therefore, explored the effect of a JAK1/2/3 inhibitor, AZD1480, on paired SP and PB MF-HPCs and MF-SCs.
Materials and methods

Patient specimens and cell preparation
Surgically removed spleens were obtained from patients with advanced forms of MF requiring therapeutic splenectomy. All patients provided signed informed consent as approved by the institutional review board of the Icahn School of Medicine at Mount Sinai (ISMMS) and in accordance with the Declaration of Helsinki. Single-cell suspensions were prepared according to the method of Barosi and coworkers 28 from the spleens of 12 patients with PMF or PV/ET-related MF who fulfilled the World Health Organization (WHO) diagnostic criteria 29 (Table 1) . PB was collected from these patients, except patients 11 and 12. Cord blood (CB) collections were provided by the New York Blood Center. Mononuclear cells (MNCs) were isolated by density gradient centrifugation using Ficoll-Paque (GE Healthcare Life Sciences). CD34 1 cells were selected using a CD34 1 cell selection kit (StemCell Technologies). CD34 1 cells with a purity of $90%
as analyzed using a FACSCanto Flow Cytometer (BD) were used in each experiment.
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JAK2V617F, CALR mutational analyses, and cytogenetic and FISH analyses
The JAK2V617F status of each MF patient was determined by analyzing PB granulocytes using a previously described real-time allele-specific polymerase chain reaction (AS-PCR) assay. 30, 31 Mutational analysis of calreticulin (CALR) was performed by DNA resequencing regions of known mutations in CALR as previously described. 22 Cytogenetic and fluorescence in situ hybridization (FISH) analyses were performed as previously described. 32, 33 The JAK2V617F allele burden, CALR status, and the presence of a marker chromosomal abnormality in each patient is shown in Table 1 .
Treatment of MF and CB CD34
1 cells with AZD1480
SP or CB CD34 1 cells (1 3 10 5 /mL) were cultured in Iscove modified Dulbecco medium (IMDM; Lonza) containing 30% fetal bovine serum (FBS; HyClone Laboratories) supplemented with 100 ng/mL stem cell factor (SCF), 100 ng/mL feline McDonough sarcoma-like tyrosine kinase 3 ligand (FL), 100 ng/mL thrombopoietin (TPO), and 50 ng/mL interleukin-3 (IL-3; Amgen) in a humidified incubator maintained at 37°C with 5% CO 2 . After 16 hours, cells were exposed to AZ1480 (50 nM, 150 nM, 300 nM, and 500 nM, gift of AstraZeneca) for 3 days. In addition, cultures containing cytokines alone were performed in parallel. The determined optimal dose of AZD1480 identified (150 nM) was then used in subsequent investigations.
To determine whether AZD1480 affected normal HPCs, CB CD34 
HPC assays
Cultured cells were assayed for HPCs in semisolid media. 34 Briefly, 2500 cells were plated in duplicate culture dishes containing 1 mL of IMDM with 1.1% methylcellulose, 30% FBS, 5 3 10 25 mol/L 2-mercaptoethanol (StemCell Technologies), to which SCF, TPO, IL-3, IL-6, granulocyte macrophage colony-stimulating factor (GM-CSF), each at 100 ng/mL, and 4 U/mL erythropoietin (Amgen) were added. Colonies were enumerated after 12 to 14 days of incubation. Individual colonies were plucked and analyzed for the presence of JAK2V617F using a nested AS-PCR 34 and the presence of a marker chromosomal abnormality using FISH as described above in "JAK2V617F, CALR mutational analyses, and cytogenetic and FISH analyses." 32 The percentage of JAK2V617F-positive colonies or colonies having chromosomal abnormalities was then determined. /mL) were cultured in the presence of cytokines alone or cytokines 1 AZD1480 for 4 hours. Cells were then lysed with radioimmunoprecipitation assay (RIPA) buffer with a protease inhibitor cocktail and a phosphatase inhibitor cocktail (Pierce Biotechnologies). Protein was resolved using 4% to 12% Nu-PAGE Bis-Tris gels (Invitrogen) and transferred to polyvinylidene difluoride (PVDF) membranes (Millipore). Membranes were blocked, incubated with indicated primary antibodies (Abs), and horseradish peroxidase (HRP)-conjugated secondary Abs (Cell Signaling Technologies), and detected using an enhanced chemiluminescence system (Pierce Biotechnology).
NSG repopulating cell assay
Statistical analysis
Results are reported as the mean 6 standard deviation (SD) of data obtained from 3 to 5 individual experiments. Statistical significance was determined using 2-tailed Student t tests. All P values were 2-sided, and P values ,.05 were considered significant.
Results
SP MF CD34
1 cells respond to AZD1480 treatment in a dosedependent fashion AZD1480 was capable of suppressing the proliferation of SP MF CD34 1 cells in a dose-dependent fashion ( Figure 1A -B). By contrast, normal CD34 1 cells were less responsive to the effects of AZD1480 ( Figure 1A -B). AZD1480 at 150 nM was able to inhibit SP MF CD34 1 cells by 55.0% 6 12.5%, whereas was only able to reduce normal CD34 1 cells by 28.6% 6 13.50%. AZD1480 (150 nM)
was then selected to further investigate the effect of AZD1480 on MF-HPCs and MF-SCs. Moreover, as shown in Figure 1C -E and G, the number of total CB cells, CD34 1 , CD34 1 CD90 1 cells, and assayable HPCs in cultures exposed to AZD1480 were minimally affected as compared with cells exposed to cytokines alone. The absolute number of CB CD34 1 CXCR4 1 cells was not affected by treatment with AZD1480 ( Figure 1F ). These findings suggest that AZD1480 treatment at the doses tested exhibited limited effects on normal CD34 1 cells. in the presence of AZD1480 at doses ranging from 50 nM to 500 nM for 3 days. After treatment, cells were analyzed by mAb staining and flow cytometry. The percentage of total cells (A) and CD34 1 cells (B) generated in the cultures exposed to cytokines plus AZD1480 relative to those generated in the cultures exposed to cytokines alone is shown. *P , .05; **P , .01; ***P , .001 vs cytokines alone for SP MF or CB CD34 1 cells, respectively (n 5 4). (C-G) AZD1480 treatment did not affect normal CD34 1 cells. The reduction in the absolute total number of CB cells
, and assayable HPCs (G) in cultures exposed to cytokines plus AZD1480 compared with that detected in cultures exposed to cytokines alone was not statistically different. P all ..05 (n 5 5). generated following the culture of SP or PB CD34 1 cells exposed to cytokines plus AZD1480 relative to that generated in the culture exposed to cytokines alone is shown.*P , .05; **P , .01; ***P , .001 (n 5 10).
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1 cells to a significant degree as compared with cells cultured with cytokines alone (P , .05 at least). Furthermore, the treatment of SP or PB MF CD34 1 cells with AZD1480 resulted in equal reductions in the number of these cells (P all ..05). These findings suggest that both SP and PB MF CD34 1 cells respond to a similar degree to AZD1480 treatment. We next assessed the inhibitory effect of AZD1480 on the numbers of both SP and PB MF-HPCs. As shown in Figure 3A -B, the number of assayable HPCs, colony-forming unit-granulocytemacrophage (CFU-GM), and burst-forming unit-erythrocyte (BFU-E), generated in the cultures of SP or PB MF CD34 1 cells exposed to cytokines plus AZD1480 was significantly decreased as compared with that generated in the cultures of SP or PB MF CD34 1 cells with cytokines alone (SP: CFU-GM and BFU-E, P both ,.001; PB: CFU-GM, P , .001; BFU-E, P , .01). Moreover, a similar level of reduction in the number of CFU-GM and BFU-E was observed following the treatment of equal number of either SP or PB MF CD34 1 cells with AZD1480 (P both ..05). These findings suggest that AZD1480 is equally capable of inhibiting both SP and PB MF-HPCs. Individual colonies from 4 JAK2V617F-positive MF patients (JAK2V617F allele burden: 62%-90%) treated with cytokines alone or cytokines plus AZD1480 were plucked and analyzed for the JAK2V617F. 34 As shown in Figure 3C -D, the treatment of JAK2V617F-positive SP or PB MF CD34
1 cells with AZD1480 resulted in similarly modest reductions in the percentage of JAK2V617F-positive colonies and JAK2V617F homozygous colonies. However, because the treatment of both SP and PB MF CD34 1 cells with AZD1480 resulted in a significant reduction in the number of CFU-GM and BFU-E ( Figure 3A-B) , as shown in Figure 3E -F, a significant reduction in absolute numbers of JAK2V617F-positive and homozygous colonies (SP: P both ,.001; PB: P both ,.01) were observed. Similarly, although the percentage of the colonies having marker chromosomal abnormalities in cultures of either SP or PB MF CD34 1 cells exposed to cytokines plus AZD1480 was nearly equal to that in AZD1480 relative to that generated in cultures treated with cytokines alone. **P , .01; ***P , .001 (n 5 4).
cultures exposed to cytokines alone ( Figure 3G ), a significant reduction in the absolute number of colonies possessing the marker chromosomal abnormality was observed following exposure to AZD1480 ( Figure 3H ). These data suggest that AZD1480 treatment is able to impair the in vitro generation of MF-HPCs and thereby leads to a reduction but not elimination of the number of malignant HPC.
Effects of AZD1480 on MF CD34 1 cells are independent of
JAK2V617F status
The clinical responses of patients with MF to ruxolitinib occur independent of their JAK2 mutational status. 23, 24 We therefore investigated whether the action of AZD1480 on both SP and PB CD34 1 cells differed when JAK2V617F-negative and JAK2V617F-positive CD34 1 cells were studied. As shown in Figure 4A -E, the numbers of total cells, CD34 HPC generation from patient 7 having a CALR mutation (46-bp deletion). These findings suggest that AZD1480 has similar effects on JAK2V617F-positive and JAK2V617F-negative as well as CALR mutant-positive SP and PB MF-HPCs.
Effects of treatment with AZD1480 on MF-NRCs
We examined the effect of AZD1480 on SP MF-SCs by transplanting SP MF CD34 1 cells from 6 patients treated with cytokines alone or cytokines plus AZD1480 into NSG mice. Because the engraftment capacity of SP CD34 1 cells from each individual patient differs greatly, we first performed statistical analyses of the degree of human cell chimerism (percentage of hCD45 1 cells) achieved in mice receiving total cells generated in cultures of equal number of SP MF CD34 1 cells exposed to cytokines alone and cytokines plus AZD1480 from each individual patient. As shown in Figure 5A -B, 4 or 6 months after the transplantation, similar numbers of hCD45 (Table 2) . As also Inhibition of JAK-STAT activity in CD34 1 cells from MF patients.
We determined phosphorylated (p) JAK2, pSTAT3, and pSTAT5 levels in primary SP MF CD34 1 cells from 1 JAK2V617F-negative and CALR mutant-positive patient (SP 7), 1 JAK2V617F-negative and CALR-negative patient (SP 8), and 2 JAK2V617F-positive and CALR-negative patient specimens (SP 11, 12) using western blotting. Sufficient numbers of cells were only available from spleens of patients 11 and 12, which were used to assess the inhibitory effects of AZD1480 treatment on CD34 
Discussion
Dysregulation of the JAK-STAT signaling pathway represents a central mechanism in the pathogenesis of myeloproliferative neoplasms (MPNs), and small-molecule inhibition of this pathway (primarily through JAK2 blockade) results in rapid relief of splenomegaly and debilitating MF-related constitutional symptoms, both in patients with JAK2V617F and in patients with wild-type JAK2. 23, 24 However, at present, current JAK inhibitors have been shown to have little impact in modifying the JAK2 mutant allele burden, marrow histology, or reducing the risk of transformation to acute myelogenous leukemia (AML). These finding are dramatically different than those that are observed with tyrosine kinase inhibitor therapy for another MPN, chronic myeloid leukemia (CML), where imatinib therapy is associated with a high proportion of patients achieving durable complete hematological cytogenetic and molecular remissions. 35 Even in patients who are in complete cytogenetic remissions, however, Bhatia and coworkers detected residual BCR/ABL 1 HPCs indicating that imatinib therapy, although capable of altering the natural history of CML, is not able to eliminate every primitive CML HPCs or SCID repopulating cells (SRCs). 36 Several small-molecule inhibitors of JAK1/2 have been reported to be capable of inhibiting but not eliminating JAK2V617F 1 progenitor cells. 34, 37 Furthermore, Mullaly and coworkers using a JAK2V617F
1 animal model have provided data which indicated that although the JAK2 inhibitor TG101348 had therapeutic efficacy against serially transplanted For personal use only. on April 19, 2017 . by guest www.bloodjournal.org From JAK2V617F-evoked MPN, resulting in reduction in spleen size and the erythroid precursor cell number, treatment with the drug did not eliminate the MPN-initiating population in vivo. 9 In this report, we have examined the effects of a potent JAK1/2/3 inhibitor on primary MF progenitor cells and NRCs. For these studies, we have used CD34
1 cells that were isolated from the spleens of MF patients which we have previously shown to contain a higher frequency of malignant MF-SCs than that present in PB. 27 Treatment with AZD1480 resulted in the depletion of both SP and PB MF-HPCs (CFU-GM and BFU-E) but did not affect the malignant NRCs. These data provide direct evidence that JAK inhibitors may affect only a subpopulation of progenitors, but spare another reservoir of malignant HPCs and stem cells. Our studies would account for the rapid but incomplete shrinkage in spleen size associated with JAK2 inhibitor therapy and the rapid enlargement in spleen size that not infrequently occurs if the drug is discontinued. These observations can be attributed to the persistence of a reservoir of malignant HPCs and NRCs which survive exposure to a JAK1/2/3 inhibitor, but which rapidly proliferate once the tyrosine kinase inhibitor therapy is halted. These data also highlight the possible limitations of JAK2 inhibitor therapy in eliminating MF-SCs. Because both interferon a 38 and sequential treatment with a DNA methyltransferase inhibitor and a histone deacetylase inhibitor 30 have been previously shown to be capable of depleting MPN stem cells, one might anticipate that these classes of drugs might be more likely to be more effective than JAK1/2 inhibitors in targeting MPN stem cells with the goal of affecting the evolution of MF to leukemia.
In PMF and post-PV or post-ET MF patients, hematopoiesis occurs not only in the marrow but also in a variety of extramedullary sites including the spleen and liver. In this report, the possibility that the dramatic effects on the spleen could be attributed to an increased sensitivity of SP MF-HPCs as compared with PB HPCs was examined by assessing the effects of AZD1480 on CD34 To date, none of the currently available JAK2 inhibitors has been shown to be specific to the mutant as opposed to wild-type JAK2. [23] [24] [25] 39 We have shown that AZD1480 treatment decreased the number of CD34 inhibitor TG101209 was independent of the JAK2 mutational status. 40 Although JAK2 inhibitor therapy clearly results in relief for patients from MF-related symptoms and the consequences of splenomegaly, the inability of AZD1480 to substantially eliminate the number of MF HPCs or to deplete MF-SCs as observed in this report leads one to question whether this class of agents has the potential to substantially alter the natural history of MF. More effective therapeutic strategies that would be able to not only block the JAK-STAT signaling pathway but also selectively target JAK2V617F and target at least MF-HPCs and possibly MF-SCs are clearly needed if drug treatments that substantially reduce the malignant MF cell burden are to become a reality.
